Clinical trials demonstrating the efficacy of PTH for the treatment of HypoPT have led to the 2015 approval by the FDA in the United States of full-length recombinant human PTH [rhPTH (1–84)] for the management of hypoparathyroidism. Here, PTH is linked to hypoparathyroidism.